Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists unlock secrets of flu Vaccine's age gap

NCT ID NCT06501963

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at why the live attenuated influenza vaccine (LAIV), given as a nasal spray, is less effective in adults than in children. Researchers measured antibody levels in 51 healthy adults after vaccination to understand the immune response. The goal is to use these insights to design better flu vaccines for everyone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Live attenuated influenza vaccine (FluMist nasal spray)
What this could lead to
If successful, this research could help design more effective flu vaccines for adults.
What could go wrong
This is a small, completed study focused on understanding immune responses, not testing a new treatment. Results may not directly lead to better vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

51 people

The number who actually took part.

Started

Oct 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand and give informed consent * Participants of child bearing potential must agree to use effective birth control for the duration of the study. A negative urine pregnancy test must be documented prior to vaccination. Exclusion Criteria: * History of allergy or serious adverse reaction, including Guillain-Barré syndrome, to a vaccine or vaccine products * History of a medical condition resulting in impaired immunity such as active solid tumors, leukemia, lymphoma, chemotherapy or radiation therapy, autoimmune conditions, or splenic dysfunction. Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study. * History of asthma, cochlear implant, or active cerebrospinal fluid leak * Use of immune modifying drugs including: systemic steroids for more than 1 week (such as prednisone \> 20mg/day), chronic administration (more than 14 days total) of immunosuppressive or immunomodulatory drugs in the prior 3 months * History of HIV, Hepatitis B or Hepatitis C infection * Chronic clinically significant medical problems that could be considered active or unstable (i.e diagnosed within the past 3 months or requiring a change in medication within the past 3 months). This is including (but not limited to): * Insulin dependent diabetes * Severe heart disease (including arrhythmias) * Severe lung disease * Severe liver disease * Severe kidney disease * Severe hypertension: defined as life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit). * Congenital genetic syndromes (e.g., trisomy 21) * Body Mass Index (BMI) \> 35 * Pregnancy or breast feeding, or plans to become pregnant in the next month * History of influenza infection or vaccination within the current or previous influenza season * Receipt of blood products or immune globulin product within the prior 3 months * History of excessive alcohol consumption, drug use, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial * Receipt of any live vaccines 30 days before, or plans to receive any live vaccines 30 days after vaccination * Receipt of any inactivated vaccines 14 days before, or plans to receive any inactivated vaccines 14 days after vaccination * Receipt of any non-registered or other investigational product in 30 days before, or plans to receive any other investigational product 30 days after vaccination * Temporary Exclusion Criteria: * Fever (temperature ≥38.0°C) or coryzal symptoms within 72 hours prior to vaccination * Receipt of antipyretics within 6 hours prior to vaccination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hope Clinic of the Emory Vaccine Center

    Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.